Technical Analysis for QURE - uniQure N.V.

Grade Last Price % Change Price Change
grade D 55.06 4.36% 2.30
QURE closed up 4.36 percent on Tuesday, April 23, 2019, on approximately normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Up Down Down
See historical QURE trend table...

Date Alert Name Type % Chg
Stochastic Buy Signal Bullish 0.00%
Bollinger Band Squeeze Range Contraction 0.00%
BB Squeeze + Lower Band Touch Range Contraction 0.00%
Lower Bollinger Band Touch Weakness 0.00%
Oversold Stochastic Weakness 0.00%
Bollinger Band Squeeze Range Contraction 4.36%
BB Squeeze + Lower Band Touch Range Contraction 4.36%
Below Lower BB Weakness 4.36%
Down 3 Days in a Row Weakness 4.36%
Down 4 Days in a Row Weakness 4.36%

Older signals for QURE ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
uniQure BV, a biopharmaceutical company, develops gene therapies through its modular technology platform for the treatment of genetic or acquired diseases. The company offers Glybera for the treatment of patients with lipoprotein lipase deficiency, an orphan metabolic disease. It also develops a pipeline of additional adeno-associated virus (AAV) based gene therapies, including AMT-060, a gene therapy for the treatment of hemophilia B; AMT-021 for acute intermittent porphyria; AMT-110 for Sanfilippo B syndrome; and AAV2/glial cell line-derived neurotrophic factor for Parkinson's disease, as well as various programs that are in early preclinical development stage. The company has collaborations with Chiesi Farmaceutici S.p.A., Digna Biotech, Institut Pasteur, and University of California San Francisco. uniQure BV was founded in 1998 and is headquartered in Amsterdam, the Netherlands.
Biopharmaceutical Biology Diseases Gene Therapy Genetics Parkinson's Disease Applied Genetics Gene Delivery Treatment Of Hemophilia Adeno Associated Virus AAV Lipoprotein Lipase Deficiency Acute Intermittent Porphyria Alipogene Tiparvovec Glybera Hemophilia B
Is QURE a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 1 bullish, 2 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 69.6
52 Week Low 21.98
Average Volume 601,744
200-Day Moving Average 38.1587
50-Day Moving Average 55.9512
20-Day Moving Average 58.1805
10-Day Moving Average 56.204
Average True Range 2.6269
ADX 23.12
+DI 20.6761
-DI 27.3146
Chandelier Exit (Long, 3 ATRs ) 60.2893
Chandelier Exit (Short, 3 ATRs ) 59.7307
Upper Bollinger Band 63.428
Lower Bollinger Band 52.933
Percent B (%b) 0.2
BandWidth 18.03869
MACD Line -0.818
MACD Signal Line 0.2352
MACD Histogram -1.0532
Fundamentals Value
Market Cap 1.41 Billion
Num Shares 25.6 Million
EPS -2.82
Price-to-Earnings (P/E) Ratio -19.52
Price-to-Sales 16.30
Price-to-Book 14.70
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 59.34
Resistance 3 (R3) 59.00 57.24 58.63
Resistance 2 (R2) 57.24 56.15 57.41 58.39
Resistance 1 (R1) 56.15 55.47 56.69 56.49 58.15
Pivot Point 54.38 54.38 54.65 54.55 54.38
Support 1 (S1) 53.29 53.29 53.84 53.63 51.97
Support 2 (S2) 51.53 52.62 51.70 51.73
Support 3 (S3) 50.44 51.53 51.49
Support 4 (S4) 50.78